Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Biotech & pharma
COPENHAGEN, Denmark & NORTH CHICAGO, Ill., October 05, 2026--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diff
Oct 5 · 18:50·Business Wire
Healthcare · Biotech & pharma
CAMBRIDGE, Mass., October 05, 2026--Zag Bio™, Inc., a biotechnology company working to set a new standard for treating autoimmune disease, today announced it has advanced its lead program for Type 1 diabetes (T1D), ZAG-101, into clinical development. The company’s first-in-human Phase 1b/2a clinical trial (LANTERN) will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZAG-101 and explore its potential to preserve insulin-producing beta-cell function.
Oct 5 · 17:10·Business Wire
Healthcare · Biotech & pharma
Company announcement No. 53 / 2026
Oct 5 · 16:30·GlobeNewswire
Finance · AI
New research finds 51% of U.S. drug launches exceeded Wall Street revenue expectations in 2025, with oncology products leading the way WALTHAM, Mass., Oct. 5, 2026 -- Trinity, the leader in integrating human and artificial intelligence in life sciences commercialization,...
Oct 5 · 15:15·PR Newswire
Healthcare · Biotech & pharma
Recognized for bold approach to addressing therapeutic targets
Recognized for bold approach to addressing therapeutic targets
Oct 5 · 15:00·GlobeNewswire
Finance · Biotech & pharma
LOS ANGELES, Oct. 05, 2026 -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of the federal securities laws.
Oct 5 · 15:00·GlobeNewswire
Healthcare · Biotech & pharma
ALAMEDA, Calif., October 05, 2026--Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced long-term (36 months) followup data from its pivotal PRIMAvera clinical trial (NCT04676854). The results were presented in a late-breaking session at the 26th EURETINA Congress of European retina specialists in Vienna by Mahi Muqit, MD, PhD, Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust and Associate Professor at the Institu
Oct 5 · 14:00·Business Wire
Healthcare · Automotive
First patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 -- Anixa...
Oct 5 · 12:15·PR Newswire
Healthcare · Biotech & pharma
Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic Clinical data expected in 1H 2027 BURLINGTON, Mass., Oct. 5, 2026 -- Consano Bio, Inc., a clinical-stage biotechnology company...
Oct 5 · 12:10·PR Newswire
Biotech & pharma
As GLP-1 and specialty-drug utilization expands, SHARx warns employers that spending control needs forecasting, access strategies and total-spend discipline, not rebate guarantees alone. ST. LOUIS, Oct. 5, 2026 -- A larger rebate does not guarantee lower pharmacy spending,...
Oct 5 · 12:08·PR Newswire
SaaS · Healthcare
HighlightsM3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine...
Oct 5 · 12:00·Newsfile
Healthcare · Biotech & pharma
BOSTON, Oct. 05, 2026 -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced positive Phase 1 clinical and preclinical data for FT2109, its novel, potential best-in-class oral selective TNFR1 signaling inhibitor. The data are included in two abstracts accepted for presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place November 6–11 in Orlando, Florida.
Oct 5 · 12:00·GlobeNewswire